Use of Quantitative RT-PCR for Staging Esophageal Cancer

使用定量 RT-PCR 对食管癌进行分期

• 批准号: 7215585
• 负责人: JAMES D LUKETICH
• 金额: $ 26.07万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-03-09 至 2010-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7215585
• 关键词: Address; Beer; Biological Process; Cancer Patient; Classification; Clinical; Complex; Data; Decision Making; Detection; Disease; Distant Metastasis; Esophageal Adenocarcinoma; Esophageal Neoplasms; Event; Gene Expression; Gene Expression Profiling; Genes; Genetic; Gold; Histologic; Imaging Techniques; Immunohistochemistry; Incidence; Lung Adenocarcinoma; Lymph Node Dissections; Lymph Node Involvement; Malignant Neoplasms; Malignant neoplasm of esophagus; Malignant neoplasm of lung; Medicine; Metastatic Neoplasm to Lymph Nodes; Methods; Microarray Analysis; Molecular; Molecular Profiling; Nature; Negative Lymph Node; Neoplasm Metastasis; Nodal; Outcome; PET/CT scan; Pathologic; Pathology; Patients; Pattern; Positive Lymph Node; Predictive Value; Primary Neoplasm; Probability; Process; Publishing; Recurrence; Recurrent disease; Reporting; Research; Research Personnel; Resectable; Reverse Transcriptase Polymerase Chain Reaction; Risk; Sensitivity and Specificity; Site; Solid Neoplasm; Staging; Staining method; Stains; Standards of Weights and Measures; Stratification; Survival Rate; TNM; Testing; Tumor Biology; Ultrasonography; base; cancer cell; improved; interest; lymph nodes; malignant breast neoplasm; outcome forecast; treatment planning; tumor

DESCRIPTION (provided by applicant): In the USA, the incidence of esophageal adenocarcinoma has risen more than 350% since 1974 while long-term survival rates have remained at 10-15%. Current staging methods are inadequate for predicting survival in this disease, as evidenced by the fact that even patients with early stage, potentially resectable tumors frequently recur and die. Since treatment options are based on pathologic stage, clinicians need improved staging methods to assist in appropriate treatment planning for these patients. Our previously published reports indicate that disease recurrence and poor survival in esophageal cancer patients may be predicted, in part, by the presence of occult metastases to lymph nodes. Recently however, Beer et al. reported in Nature Medicine that gene expression patterns in primary tumors can predict outcome in stage I lung cancer patients. In addition, three new reports in Nature Genetics and The Lancet and Cancer Cell demonstrate that the propensity to metastasize may actually be encoded in the gene expression patterns of primary tumors. Furthermore, the Lancet study by Huang et al. identified separate gene sets that seem to predict lymph node metastasis and overall recurrence in breast cancer patients. These interrelated events would thus appear to be the result of distinct biological processes that can be detected by analysis of the primary tumor. It is our hypothesis that gene expression patterns in the primary tumor determine metastatic potential and probability of survival for patients with esophageal adenocarcinoma. Subsequently, we believe that microarray analysis of esophageal tumors will allow us to identify sets of genes that correlate with both metastasis and survival. Given the correlation between lymph node status and survival in esophageal cancer, we also hypothesize that gene expression analysis and occult disease detection approaches will identify overlapping sets of patients at high risk for recurrence. In this proposal, we intend to explore the relationship between data obtained from microarray analysis of the primary tumors and analysis of occult lymph node involvement. We believe that the combination of this comprehensive molecular staging will allow us to significantly improve upon the current staging of esophageal adenocarcinoma. In addition, we believe that this research will answer some very interesting questions about tumor biology and metastasis in esophageal cancer.

描述（由申请人提供）：在美国，自1974年以来，食管腺癌的发病率上升了350%以上，而长期生存率保持在10- 15%。目前的分期方法不足以预测这种疾病的生存率，事实证明，即使是早期的患者，可能切除的肿瘤经常复发和死亡。由于治疗方案是基于病理分期，临床医生需要改进的分期方法，以协助适当的治疗计划，这些患者。我们以前发表的报告表明，食管癌患者的疾病复发和生存率低可能部分是通过淋巴结的隐匿性转移来预测的。然而，最近Beer等人在Nature Medicine上报道，原发性肿瘤中的基因表达模式可以预测I期肺癌患者的结果。此外，Nature Genetics和The Lancet and Cancer Cell上的三份新报告表明，转移的倾向实际上可能在原发性肿瘤的基因表达模式中编码。此外，Huang等人的Lancet研究确定了似乎可以预测乳腺癌患者淋巴结转移和总体复发的单独基因集。因此，这些相互关联的事件似乎是可以通过分析原发性肿瘤检测到的不同生物过程的结果。我们的假设是原发肿瘤的基因表达模式决定了食管腺癌患者的转移潜力和生存概率。 随后，我们相信食管肿瘤的微阵列分析将使我们能够识别与转移和生存相关的基因组。鉴于食管癌淋巴结状态与生存率之间的相关性，我们还假设基因表达分析和隐匿性疾病检测方法将识别重叠的高复发风险患者。在这个建议中，我们打算探索从原发性肿瘤的微阵列分析和隐匿性淋巴结受累分析获得的数据之间的关系。我们相信，结合这种综合的分子分期，将使我们能够显着改善目前的食管腺癌分期。此外，我们相信这项研究将回答一些关于食管癌肿瘤生物学和转移的非常有趣的问题。